A phase II, multicenter, open-label study of [fam-] trastuzumab deruxtecan (DS 8201a) in subjects with HER2-expressing gastric cancer.

被引：1

作者：

Shitara, Kohei

Bang, Yung-Jue

Chung, Hyun Cheol

Yabusaki, Hiroshi

Iwasa, Satoru

Sakai, Daisuke

Muro, Kei

Sugimoto, Naotoshi

Yasui, Hisateru

Gamoh, Makio

Murakawa, Yasuko

Negoro, Yuji

Nishina, Tomohiro

Hosaka, Hisashi

Omuro, Yasushi

Kawaguchi, Yoshinori

Sugihara, Masahiro

Saito, Kaku

Dalal, Rita

Yamaguchi, Kensei

机构：

[1] Natl Canc Ctr Hosp East, Chiba, Japan

[2] Seoul Natl Univ Hosp, Seoul, South Korea

[3] Yonsei Canc Ctr, Seoul, South Korea

[4] Niigata Canc Ctr Hosp, Niigata, Japan

[5] Natl Canc Ctr, Dept Expt Therapeut, Tokyo, Japan

[6] Osaka Univ Hosp, Osaka, Japan

[7] Aichi Canc Ctr Hosp, Dept Clin Oncol, Nagoya, Aichi, Japan

[8] Osaka Int Canc Inst, Osaka, Japan

[9] Kobe City Med Ctr Gen Hosp, Kobe, Hyogo, Japan

[10] Osaki Citizen Hosp, Osaki, Japan

[11] Miyagi Canc Ctr, Natori, Miyagi, Japan

[12] Kochi Hlth Sci Ctr, Kochi, Japan

[13] Natl Hosp Org Shikoku Canc Ctr, Matsuyama, Ehime, Japan

[14] Gunma Prefectural Canc Ctr, Ota, Japan

[15] Komagome Hosp, Tokyo Metropolitan Canc & Infect Dis Ctr, Tokyo, Japan

[16] Daiichi Sankyo Co Ltd, Tokyo, Japan

[17] Daiichi Sankyo Inc, Basking Ridge, NJ USA

[18] Japanese Fdn Canc Res, Canc Inst Hosp, Tokyo, Japan

来源：

JOURNAL OF CLINICAL ONCOLOGY | 2019年 / 37卷 / 04期

关键词：

D O I：

10.1200/JCO.2019.37.4_suppl.TPS180

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS180

引用

页数：2

共 50 条

[41] Multicenter phase II study of trastuzumab deruxtecan (DS-8201) for HER2-positive unresectable or recurrent biliary tract cancer: HERB trial.
Ohba, Akihiro
Morizane, Chigusa
Ueno, Makoto
Kobayashi, Satoshi
Kawamoto, Yasuyuki
Komatsu, Yoshito
Ikeda, Masafumi
Sasaki, Mitsuhito
Okano, Naohiro
Furuse, Junji
Hiraoka, Nobuyoshi
Yoshida, Hiroshi
Kuchiba, Aya
Ogawa, Gakuto
Nakamura, Kenichi
Matsui, Naoko
Nakamura, Yoshiaki
Okamoto, Wataru
Yoshino, Takayuki
Okusaka, Takuji
JOURNAL OF CLINICAL ONCOLOGY, 2020, 38 (15)
[42] Pharmacokinetics (PK), safety, and efficacy of [fam-] trastuzumab deruxtecan with OATP1B/CYP3A inhibitors in subjects with HER2-expressing advanced solid tumours
Bang, Y-J.
Karayama, M.
Takahashi, M.
Watanabe, J.
Minami, H.
Yamamoto, N.
Kinoshita, I.
Lin, C. -C.
Im, Y. -H.
Fujiki, T.
Achiwa, I.
Kamiyama, E.
Okuda, Y.
Lee, C.
Takahashi, S.
ANNALS OF ONCOLOGY, 2019, 30 : 116 - +
[43] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
Kohei Shitara
Kensei Yamaguchi
Kei Muro
Hisateru Yasui
Daisuke Sakai
Takashi Oshima
Masahiro Fujimura
Yuta Sato
Shunsuke Yamazaki
Tatsuya Wakabayashi
Masahiro Sugihara
Takahiro Kamio
Hirokazu Shoji
International Journal of Clinical Oncology, 2024, 29 : 27 - 35
[44] Trastuzumab deruxtecan in patients with locally advanced or metastatic HER2-positive gastric cancer: a multicenter, open-label, expanded-access study
Shitara, Kohei
Yamaguchi, Kensei
Muro, Kei
Yasui, Hisateru
Sakai, Daisuke
Oshima, Takashi
Fujimura, Masahiro
Sato, Yuta
Yamazaki, Shunsuke
Wakabayashi, Tatsuya
Sugihara, Masahiro
Kamio, Takahiro
Shoji, Hirokazu
INTERNATIONAL JOURNAL OF CLINICAL ONCOLOGY, 2024, 29 (01) : 27 - 35
[45] Trastuzumab deruxtecan (DS-8201a) in patients with advanced HER2-positive gastric cancer: a dose-expansion, phase 1 study
Shitara, Kohei
Iwata, Hiroji
Takahashi, Shunji
Tamura, Kenji
Park, Haeseong
Modi, Shanu
Tsurutani, Junji
Kadowaki, Shigenon
Yamaguchi, Kensei
Iwasa, Satoru
Saito, Kaku
Fujisaki, Yoshihiko
Sugihara, Masahiro
Shahidi, Javad
Doi, Toshihiko
LANCET ONCOLOGY, 2019, 20 (06): : 827 - 836
[46] Visualization of Intratumor Pharmacokinetics of [fam-] Trastuzumab Deruxtecan (DS-8201a) in HER2 Heterogeneous Model Using Phosphor-integrated Dots Imaging Analysis
Suzuki, Mikiko
Yagishita, Shigehiro
Sugihara, Kiyoshi
Ogitani, Yusuke
Nishikawa, Tadaaki
Ohuchi, Mayu
Teishikata, Takashi
Jikoh, Takahiro
Yatabe, Yasushi
Yonemori, Kan
Tamura, Kenji
Hasegawa, Kosei
Hamada, Akinobu
CLINICAL CANCER RESEARCH, 2021, 27 (14) : 3970 - 3979
[47] Primary analysis from DS8201-A-U105: A phase 1b, two-part, open-label study of trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing urothelial carcinoma (UC).
Galsky, Matt D.
Del Conte, Gianluca
Foti, Silvia
Yu, Evan Y.
Machiels, Jean-Pascal H.
Doger, Bernard
Necchi, Andrea
De Braud, Filippo G.
Hamilton, Erika P.
Hennequin, Audrey
Van den Mooter, Tom
Debruyne, Philip R.
Moreno, Irene
Arkenau, Hendrik-Tobias
Tsuchihashi, Zenta
Cheng, Fu-Chih
Augustine, Bincy
Cheng, Ben
Barrios, Daniel
Luftner, Diana
JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (06)
[48] Primary analysis from DS8201-A-U105: A 2-part, open label, phase Ib trial assessing trastuzumab deruxtecan (T-DXd) with nivolumab (nivo) in patients (pts) with HER2-expressing advanced breast cancer
Hamilton, E. P.
Shapiro, C. L.
Boni, V.
Jimenez, M. Martin
Del Conte, G.
Cortes, J.
Agrawal, L.
Arkenau, H-T.
Tan, A. R.
Debruyne, P. R.
Minchom, A. R.
Rutten, A.
Valdes-Albini, F.
Yu, E.
Suto, F.
Cheng, F-C.
Augustine, B.
Cheng, B.
Barrios, D.
Hurvitz, S. A.
ANNALS OF ONCOLOGY, 2022, 33 : S196 - S196
[49] A phase 3, multicenter, randomized, open-label trial of trastuzumab deruxtecan (T-DXd; DS-8201) vs investigator's choice in HER2-low breast cancer (DESTINY-Breast04)
Zaman, K.
Modi, S.
Ohtan, S.
Lee, C.
Wang, Y.
Saxena, K.
Cameron, D. A.
SWISS MEDICAL WEEKLY, 2020, : 28S - 29S
[50] An open-label, multicenter phase II trial of sunitinib for patients with chemorefractory metastatic gastric cancer.
Moehler, M. H.
Hartmann, J. T.
Lordick, F.
Al-Batran, S.
Reimer, P.
Trarbach, T.
Ebert, M. P.
Daum, S.
Weihrauch, M.
Galle, P. R.
JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)

← 1 2 3 4 5 →